Ventas, Inc. $VTR Shares Purchased by National Pension Service

National Pension Service lifted its stake in Ventas, Inc. (NYSE:VTR) by 6.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 836,222 shares of the real estate investment trust’s stock after purchasing an additional 52,527 shares during the quarter. National Pension Service owned about 0.16% of Ventas worth $74,257,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Dynamic Wealth Strategies LLC purchased a new stake in shares of Ventas during the first quarter valued at $25,000. Wiser Advisor Group LLC acquired a new stake in Ventas during the 3rd quarter worth about $27,000. Silvant Capital Management LLC acquired a new stake in Ventas during the 2nd quarter worth about $28,000. Meeder Asset Management Inc. purchased a new stake in Ventas during the 2nd quarter valued at about $30,000. Finally, IFC & Insurance Marketing Inc. purchased a new stake in Ventas during the 4th quarter valued at about $30,000. 94.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on VTR shares. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $100.00 price objective on shares of Ventas in a research note on Tuesday, June 16th. Wells Fargo & Company lifted their price objective on shares of Ventas from $96.00 to $104.00 and gave the company an “overweight” rating in a research note on Tuesday, September 1st. Weiss Ratings raised shares of Ventas from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, July 21st. Mizuho raised their target price on shares of Ventas from $98.00 to $104.00 and gave the stock an “outperform” rating in a report on Wednesday, July 22nd. Finally, Barclays boosted their target price on shares of Ventas from $99.00 to $102.00 and gave the company an “equal weight” rating in a research report on Monday, August 31st. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $99.00.

Ventas Price Performance

NYSE:VTR opened at $90.10 on Friday. The company has a debt-to-equity ratio of 0.86, a current ratio of 0.44 and a quick ratio of 0.44. The company has a 50 day moving average price of $92.89 and a 200-day moving average price of $87.97. Ventas, Inc. has a 1-year low of $66.54 and a 1-year high of $101.60. The firm has a market cap of $46.22 billion, a price-to-earnings ratio of 166.85, a price-to-earnings-growth ratio of 3.53 and a beta of 0.70.

Ventas (NYSE:VTR) last announced its quarterly earnings results on Wednesday, July 29th. The real estate investment trust reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.96 by $0.01. Ventas had a net margin of 4.08% and a return on equity of 1.99%. The firm had revenue of $1.73 billion for the quarter, compared to the consensus estimate of $1.68 billion. During the same period in the prior year, the firm posted $0.87 earnings per share. The firm’s quarterly revenue was up 21.7% compared to the same quarter last year. Equities research analysts forecast that Ventas, Inc. will post 3.89 EPS for the current year.

About Ventas

Ventas, Inc is a real estate investment trust (REIT) that owns and manages a diversified portfolio of healthcare and senior living properties. Its real estate platform includes senior housing communities, medical office buildings, life science and innovation centers, and other healthcare-related facilities.

The company generally leases or operates its properties through relationships with healthcare providers, senior living operators, universities, and research institutions. Its properties support services such as independent and assisted living, skilled nursing, outpatient care, physician practices, medical research, and biotechnology development.

Ventas serves major healthcare and life science markets in the United States and Canada.